• Here's where biologics stand so far in 2021

    From studies advancing spine treatment to new techniques in stem cell procedures, here are seven updates on biologics so far this year:
  • Regenerative medicine market to hit $39M by 2030: 5 notes

    The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.
  • What Ortho RTI hopes to achieve in 2021

    Orthopedic biotechnology company Ortho Regenerative Technologies focused on developing soft tissue repair regenerative technology in 2020. For 2021, that development is expected to grow.
  • 1st FDA-approved stem cell clinical trial for spina bifida gets underway

    UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not form properly.

Featured Webinars

Featured Whitepapers